The Broad Patent Coverage is a Major Milestone
for the Commercial Success of Jan123
LAS
VEGAS, Aug. 29, 2023 /PRNewswire/ -- JanOne
(Nasdaq: JAN), the visionary biotech company dedicated to
discovering non-addictive treatments for pain, as well as causes of
pain, has earned a US patent for its innovative formulation of
low-dose naltrexone, Jan123, for treating pain.
The Broad Patent Coverage is a Major
Milestone for the Commercial Success of Jan123
Jan123 is being developed to treat complex regional pain
syndrome (CRPS), a rare and often life-altering condition
characterized by severe pain and hypersensitivity to touch.
Tony Isaac, JanOne's CEO, said that
the broad language of the new patent—covering methods of using our
formulation of low-dose naltrexone to treat chronic pain
— provides robust and broad coverage and protection, and
lengthens the timeline for sales significantly.
"Today, patients with complex regional pain syndrome must resort
to long-term opioid and narcotics for relief," Isaac said. "If
Jan123 is approved, sufferers of CRPS will finally have proven,
non-addictive relief."
Low-dose naltrexone has been shown in multiple studies and
case reports to provide symptom relief in patients who suffer from
CPRS, an orphan disease with no current FDA approved treatments.
"This allowance from the US Patent Office speaks to the novelty of
our approach, as well as the inventive spirit of JanOne's
scientific team," said Dr. Tony
Giordano, the company's Chief Scientific Officer. "Our
low-dose naltrexone has the potential to help patients who are
suffering from CRPS, and we look forward to testing it in
large-scale human trials."
Dr. Amol Soin, the inventor of Jan123 and its novel uses,
expressed great satisfaction with the US Patent Office's action.
"This patent will allow us to help many patients who struggle with
CRPS and is a validation of years of hard work by our team."
In citing features of the drug's formulation, the new patent
explains Jan123's mechanism of action, including that "it increases
endogenous enkephalins and endorphins which are the body's
natural pain killers," resulting in a decrease in patient pain.
The full benefits of Jan123 may not yet to be known, but as
stated in the patent: "Not only does low-dose naltrexone treat
the pain symptom of CRPS, but it can also treat the disease process
and disease cascades… It may actually treat the underlying disease
state, which would be extremely beneficial to the patient."
"All in all," CEO Isaac concluded, "this patent approval is an
important milestone in our company's brief history—and a welcome
confirmation of our strategic vision."
About JanOne Inc.
JanOne is a unique
Nasdaq-listed company offering innovative, actionable solutions
intended to help end the opioid crisis. JanOne is dedicated to
funding resources toward innovation, technology, and education to
find a key resolution to the national opioid epidemic, which is one
of the deadliest and most widespread in the nation's history. Its
drugs in the clinical trial pipeline have shown promise for their
innovative targeting of the causes of pain as a strategic option
for physicians averse to exposing patients to addictive
opioids.
Forward Looking Statements
This press release contains statements that are forward-looking
statements as defined within the Private Securities Litigation
Reform Act of 1995, including, but not limited to, statements
relating to the statements that JAN 101 will treat PAD, that JAN
123 will treat CRPS, the timing of the commencement of clinical
trials, that the FDA will permit approval through a 505(b)(2)
pathway for JAN 123, that upon approval JAN 101 will immediately
disrupt the PAD market, and other statements, including words such
as "continue", "expect", "intend", "will", "hope" "should",
"would", "may", "potential" and other similar expressions. Such
statements reflect JanOne's current view with respect to future
events, are subject to risks and uncertainties, and are necessarily
based upon a number of estimates and assumptions that, while
considered reasonable by JanOne, are inherently subject to
significant business, economic, competitive, political and social
uncertainties and contingencies. Many factors could cause JanOne's
actual results, performance or achievements to be materially
different from any future results, performance or achievements
described in this press release. Such factors could include, among
others, those detailed in the Company's periodic reports filed with
the Securities and Exchange Commission (the "SEC"). Should one or
more of these risks or uncertainties materialize, or should the
assumptions set out in the section entitled "Risk Factors" in
JanOne's filings with the SEC underlying those forward-looking
statements prove incorrect, actual results may vary materially from
those described herein. These forward-looking statements are made
as of the date of this press release and JanOne does not intend,
and does not assume any obligation, to update these forward-looking
statements, except as required by law. JanOne cannot assure that
such statements will prove to be accurate as actual results and
future events could differ materially from those anticipated in
such statements. Individuals are cautioned that forward-looking
statements are not guarantees of future performance and accordingly
investors are cautioned not to put undue reliance on
forward-looking statements due to the inherent uncertainty
therein.
Please visit www.janone.com for additional
information.
Media Contact Investor Relations
IR@janone.com
1-800-400-2247
View original content to download
multimedia:https://www.prnewswire.com/news-releases/janone-earns-us-patent-for-the-use-of-its-novel-formulation-of-low-dose-naltrexone-jan123-to-treat-chronic-pain-301912253.html
SOURCE JanOne Inc.